Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation; it is essential for maintenance of membrane potential, nerve impulse transmission, cardiac contractility, and skeletal muscle function. Dextrose provides calories and may decrease protein catabolism. Sodium chloride helps maintain extracellular fluid volume and electrolyte balance.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Prevention and treatment of hypokalemia,Replacement of potassium, fluid, and electrolytes in patients requiring intravenous therapy
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion; dose determined by serum potassium levels and patient condition; typical maintenance: 10-20 m Eq potassium per hour; maximum infusion rate: 20 m Eq/hour (not to exceed 1 m Eq/kg/hour); concentration not to exceed 80 m Eq/L via peripheral line. Each 1 L of this product contains 5 m Eq potassium chloride, 50 g dextrose, and 77 m Eq sodium chloride.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Not applicable for endogenous potassium; infused potassium distributes with a rapid initial phase (~1 h) and a slower terminal phase (~8-12 h) reflecting cellular equilibration
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Potassium is not metabolized; it is excreted renally. Dextrose is metabolized to carbon dioxide and water via glycolysis and oxidative phosphorylation. Sodium and chloride are excreted renally.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal: >90% as potassium ion; minor fecal loss <10%
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Minimal; <5%
Low protein binding; 0–11% bound, primarily to albumin.
0.2-0.5 L/kg, reflecting extracellular and intracellular distribution
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Oral: ~90% (well absorbed); IV: 100%
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
GFR 10-50 m L/min: use with caution, monitor potassium levels closely; GFR <10 m L/min: avoid use or reduce dose to prevent hyperkalemia. Potassium supplementation is generally not recommended in severe renal impairment unless documented hypokalemia.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific dosing adjustment required for Child-Pugh class A, B, or C. Monitor serum potassium as hepatic impairment may affect acid-base balance.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Dose determined by age, weight, and serum potassium; typical infusion rate: 0.5-1 m Eq/kg over 1 hour; maximum daily dose: 3 m Eq/kg/day; maximum infusion rate: 1 m Eq/kg/hour. Use in children only if hypokalemia is documented and monitored.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Use with caution due to age-related decline in renal function; monitor renal function and serum potassium; consider lower initial doses and slower infusion rates (e.g., 5-10 m Eq/hour).
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
NO BLACK BOX WARNINGS FOR THIS PRODUCT.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Administration may cause hyperkalemia, especially in patients with renal impairment, or with rapid infusion.,Use with caution in patients with cardiac disease, conditions predisposing to hyperkalemia (e.g., adrenal insufficiency, acidosis), or those receiving potassium-sparing diuretics, ACE inhibitors, or ARBs.,Monitor serum potassium, glucose, and electrolytes regularly.,Do not administer unless solution is clear and container is intact.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperkalemia,Renal failure (severe or anuria),Severe metabolic acidosis,Concurrent use of potassium-sparing diuretics or potassium supplements (unless closely monitored),Addison's disease
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
Avoid potassium-rich foods (e.g., bananas, oranges, tomatoes, potatoes, spinach, avocados) and potassium-containing salt substitutes while receiving this infusion, unless specifically instructed by your physician. Also, limit sodium intake if hypertensive or edematous.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Potassium chloride, dextrose, and sodium chloride are not teratogenic. There is no evidence of fetal risk from electrolyte and fluid administration at recommended doses. However, maternal electrolyte imbalances (e.g., hyperkalemia, hyperglycemia, hypernatremia) can adversely affect the fetus. Use only if clearly needed.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Potassium, dextrose, and sodium are normal components of breast milk. Potassium chloride and sodium chloride are excreted into breast milk but are not expected to cause adverse effects in nursing infants. No M/P ratio is available; however, these substances are naturally present. Use with caution only if clearly needed.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
No standard dose adjustment required; pregnancy does not significantly alter pharmacokinetics of potassium, dextrose, or sodium. Dose based on individual electrolyte and fluid needs, with careful monitoring to avoid maternal electrolyte disturbances that could affect the fetus.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Monitor serum potassium and glucose levels during infusion, especially in renal impairment or diabetic patients. Use with caution in patients on digoxin, as hyperkalemia can precipitate digoxin toxicity. Do not administer concentrated potassium solutions peripherally; typical maximum peripheral concentration is 10 m Eq/100 m L. Check for vein irritation or phlebitis at infusion site. Use a volumetric pump to control infusion rate; rapid infusion can cause cardiac arrest.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This medication contains potassium, dextrose (sugar), and sodium chloride (salt), administered intravenously to replenish electrolytes and provide calories.,Tell your healthcare provider if you have kidney disease, heart problems, diabetes, or are on medications such as ACE inhibitors, ARBs, or potassium-sparing diuretics.,Report any symptoms of high potassium (muscle weakness, irregular heartbeat, tingling) or high blood sugar (increased thirst, frequent urination, confusion) immediately.,Do not consume potassium-rich foods or salt substitutes without consulting your doctor, as this may increase the risk of hyperkalemia.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium is the major intracellular cation; it is essential for maintenance of membrane potential, nerve impulse transmission, cardiac contractility, and skeletal muscle function. Dextrose provides calories and may decrease protein catabolism. Sodium chloride helps maintain extracellular fluid volume and electrolyte balance.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Intravenous infusion; dose determined by serum potassium levels and patient condition; typical maintenance: 10-20 m Eq potassium per hour; maximum infusion rate: 20 m Eq/hour (not to exceed 1 m Eq/kg/hour); concentration not to exceed 80 m Eq/L via peripheral line. Each 1 L of this product contains 5 m Eq potassium chloride, 50 g dextrose, and 77 m Eq sodium chloride.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride, dextrose, and sodium chloride are not teratogenic. There is no evidence of fetal risk from electrolyte and fluid administration at recommended doses. However, m. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.